isvav_result

publication_year

occurrences__organization__code

solver__id__sc2

result_type__code

Type of result according to the RIV classification. Czech version is available <a href="https://www.vyzkum.cz/FrontClanek.aspx?idsekce=1395" target="_blank" >here</a>.

language__code

Jazyk výsledku udáva původní jazyk, ve kterém byl daný výsledek vytvořen. Kompletní seznam jazyků ve kterém je možno výsledek do RIV předložit je <a href="https://www.vyzkum.cz/FrontClanek.aspx?idsekce=1397" target="_blank" >zde</a>.

cep__code

ford__code

_group_id67

occurrences__funder__code

Data supplier is the R&D aid provider who supported this result.

project__programme__code

x_range_count_solvers

project__id

What are you looking for?

Quick search

Smart search

Filters

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from

Hepatocelulární karcinom - systémová léčba v roce 2024

Imunoterapie v léčbě karcinomu plic

Plicní toxicita imunoterapie